Emergent BioSolutions (EBS) Goodwill & Intangibles (2010 - 2026)
Emergent BioSolutions' (EBS) quarterly Goodwill & Intangibles came in at $470.4 million in Q1 2026, down 3.05% year-on-year from $485.2 million in Q1 2025, and up 7.77% quarter-over-quarter from $436.5 million in Q4 2025.
Emergent BioSolutions (EBS) Goodwill & Intangibles (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Goodwill & Intangibles history runs 17 years deep, the most recent figure standing at $470.4 million for Q1 2026.
- On a quarterly basis, Goodwill & Intangibles fell 3.05% year-over-year to $470.4 million in Q1 2026; TTM through Mar 2026 was $470.4 million, a 3.05% decrease from a year earlier, with the FY2025 full-year figure at $436.5 million, down 12.96% from the prior year.
- Goodwill & Intangibles grew to $470.4 million in Q1 2026 per EBS's latest filing, from $436.5 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $949.8 million in Q3 2022 and bottomed at $436.5 million in Q4 2025.
- The 5-year median for Goodwill & Intangibles is $550.4 million (2024), against an average of $630.5 million.
- Across the five-year window, Goodwill & Intangibles grew 14.17% in 2022 and plunged 40.17% in 2023, its largest moves.
- Year by year, Goodwill & Intangibles stood at $947.0 million in 2022, then plunged by 40.17% to $566.6 million in 2023, then declined by 11.49% to $501.5 million in 2024, then fell by 12.96% to $436.5 million in 2025, then increased by 7.77% to $470.4 million in 2026.
- Per Business Quant, the three latest EBS Goodwill & Intangibles figures stand at $470.4 million (Q1 2026), $436.5 million (Q4 2025), and $452.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 470.40 Mn |
| Dec 31, 2025 | 436.50 Mn |
| Sep 30, 2025 | 452.70 Mn |
| Jun 30, 2025 | 469.00 Mn |
| Mar 31, 2025 | 485.20 Mn |
| Dec 31, 2024 | 501.50 Mn |
| Sep 30, 2024 | 517.80 Mn |
| Jun 30, 2024 | 534.10 Mn |
| Mar 31, 2024 | 550.40 Mn |
| Dec 31, 2023 | 566.60 Mn |
| Sep 30, 2023 | 582.80 Mn |
| Jun 30, 2023 | 811.00 Mn |
| Mar 31, 2023 | 827.10 Mn |
| Dec 31, 2022 | 947.00 Mn |
| Sep 30, 2022 | 949.80 Mn |
| Jun 30, 2022 | 801.50 Mn |
| Mar 31, 2022 | 815.50 Mn |
| Dec 31, 2021 | 829.50 Mn |
| Sep 30, 2021 | 885.10 Mn |
| Jun 30, 2021 | 899.70 Mn |